September 16th 2025, 8:00pm
Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.
September 15th 2025, 1:00pm
Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.
September 14th 2025, 2:00pm
Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.
September 13th 2025, 6:00pm
For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.
September 12th 2025, 8:00pm
Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.
September 12th 2025, 3:00pm
For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.
September 12th 2025, 1:00pm
Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer.
September 10th 2025, 1:00pm
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.
September 8th 2025, 8:00pm
CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies.
September 8th 2025, 7:00pm
In patients with EGFR-mutated NSCLC ivonescimab plus chemotherapy was associated with significant progression-free survival.
What the Changing Seasons Taught Me About Cancer and Life
Understanding the Importance of Biomarker Testing in Lung Cancer
How to Individually Tailor Myelofibrosis Treatment Options
A Day in the Life of a Breast Cancer Survivor